Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.

被引：6
|
作者：
Zhou, Ai-Ping
Bai, Yuxian
Song, Van
Li, Hangzhong
Xie, Xiaodong
Ren, Xiu-Bao
Ye, Dingwei
Liu, Jiyan
Luo, Hong
Bai, Xianzhong
Qin, Shukui
Fu, Cheng
Wang, Jinwan
Ma, Jianhui
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Gen Hosp Shenyang Mil Reg, Shenyang, Liaoning, Peoples R China
[5] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Ctr Canc, Chengdu, Sichuan, Peoples R China
[8] Chongqing Canc Hosp, Chongqing, Peoples R China
[9] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[10] Nanjing Bayi Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[11] Liaoning Canc Hosp Inst, Shenyang, Liaoning, Peoples R China
[12] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16082
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment
    Mancuso, A. P.
    De Paola, E. Donato
    Catalano, A.
    Calabro, F.
    Messina, C.
    Zivi, A.
    Cerbone, L.
    Vigna, L.
    Caristo, R.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)
    Angevin, E.
    Gruenwald, V.
    Ravaud, A.
    Castellano, D. E.
    Lin, C. C.
    Gschwend, J. E.
    Harzstark, A. L.
    Chang, J.
    Wang, Y.
    Shi, M. M.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial
    Escudier, B. J.
    Negrier, S.
    Gravis, G.
    Chevreau, C.
    Delva, R.
    Bay, J.
    Geoffrois, L.
    Lagouffe, E.
    Blanc, E.
    Ferlay, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Bukowski, R. M.
    Sosman, J. A.
    Stadler, W. M.
    Margolin, K.
    Hutson, T. E.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results
    Barrios, C. H.
    Hernandez-Barajas, D.
    Brown, M. P.
    Lee, S. H.
    Fein, L.
    Liu, J. H.
    Hariharan, S.
    Martell, B.
    Yuan, J.
    Rha, S. Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 429 - 430
  • [26] Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Dang, Long H.
    Lauer, Richard C.
    Starodub, Alexander
    Hauke, Ralph J.
    Galsky, Matt D.
    Bylow, Kathryn A.
    Cowey, Charles Lance
    Bibby, David C.
    Kremmidiotis, Gabriel
    Doolin, Elizabeth E.
    Lavranos, Tina C.
    Sonpavde, Guru
    Logan, Theodore
    Hahn, Noah M.
    Sweeney, Christopher
    Sarantopoulos, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [27] Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
    Vano, Yann-Alexandre
    Phan, Letuan
    Simonaggio, Audrey
    Bennamoun, Mostefa
    Pannier, Diane
    Chevreau, Christine
    Borchiellini, Delphine
    Maillet, Denis
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Tournigand, Christophe
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Sun, Cheng-Ming
    Meylan, Maxime
    Fridman, Wolf-Herve
    Sautes-Fridman, Catherine
    Elaidi, Reza
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Phase II study of bortezomib and thalidomide in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Misellati, A
    Marsh, L
    Shen, S
    Jac, J
    Ross, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9122S
  • [29] Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy
    Ozono, Seiichiro
    Oyama, Masafumi
    Nozawa, Masahiro
    Fujimoto, Kiyohide
    Kishida, Ken
    Tokuda, Noriaki
    Kimura, Go
    Nishimura, Kazuo
    Matsubara, Akio
    Matsuyama, Hideyasu
    Sugiyama, Takayuki
    Kamba, Tomomi
    Kume, Haruki
    Masumori, Naoya
    Oya, Mototsugu
    Kanayama, Hiro-Omi
    Naito, Seiji
    Hinotsu, Shiro
    Shimozuma, Kojiro
    Akaza, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [30] SEQUENTIAL THERAPY WITH SUNITINIB-SORAFENIB IN METASTATIC RENAL CELL CARCINOMA (MRCC): PRELIMINARY RESULTS
    Condorelli, Rosaria
    Buscarino, Calogero
    Ferrau, Francesco
    Novello, Giuseppe
    Vigneri, Paolo
    Restuccia, Nunzio
    Banna, Giuseppe Luigi
    ANNALS OF ONCOLOGY, 2009, 20
12345